Many, if not most, small and midsized biopharma companies opt to partner with outside vendors—contract development and manufacturing organization, or CDMOs—to handle their end-to-end biologic development and manufacturing.

CDMOs are valuable for small, entrepreneurial companies that have innovative ideas and promising molecules, but don’t always have the in-house expertise or capacity required to fully develop a product, but many larger biopharma companies choose to work with CDMOs as well. They're leveraged to advance multiple programs simultaneously or to mitigate risk by establishing secondary sourcing for their key biologic products.

As a drug sponsor, CDMOs can offer you a wealth of expertise and services. But how do you choose the right company? What should you look for, and what questions should you ask? In our new playbook, we highlight:

• Tips on how you can assess and choose the right CDMO for your projects (and for your future needs)
• Insights from some of Catalent’s top experts, as well as feedback from a December 2018 survey, about the survey participants’ experiences in working with drug development providers
• The importance of keeping the future in mind when selecting a CDMO partner 

​​